Navigation Links
FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS
Date:11/30/2009

(sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany. Other product candidates include PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase II clinical development for the treatment of PKU and GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase I/II clinical development for the treatment of MPS IVA. For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

Forward-Looking Statement

This press release contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc., including, without limitation, statements about: the expectations of the development and potential approval of Huxley's 3,4-Diaminopyridine product for the treatment of LEMS. These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements. These risks and uncertainties include, among others: the content and timing of decisions by the U.S. Food and Drug Administration, the European Commission and other regulatory authorities, particularly the pending decision by the European Commission on the Marketing Authorization Application for such product, our success in the commercialization of such product, if approved; results and timing of current and planned preclinical studies and clinical trials related to such product; our ability to successfully manufacture the product; and those factors detailed in BioMarin's filings with the Securities and Exchange Commission, including, without limitation, the factors contained under the caption "Risk Factors" in BioMarin's 2008 Annual Report on Form 10-K, and the factors contained in BioMarin's reports on Form 10-Q. Stockholders are urged not to place undue reliance on forward-lo
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Mirus Bio Awarded Grants & Contracts of Over $5 Million
2. FDA Grants Orphan Drug Designation to TREANDA, an Investigational Treatment for Chronic Lymphocytic Leukemia
3. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
4. NIH grants $750,000 to develop device to determine temperature of neonates brain
5. Edwards Lifesciences Grants UC Irvine $5 Million to Establish the Edwards Lifesciences Center for Advanced Cardiovascular Technology
6. Radius Grants Major Pharmaceutical Company Exclusive Option to License BA058 for Osteoporosis
7. Poniard Pharmaceuticals Announces European Commission Grants Orphan Medicinal Product Designation to Picoplatin for Treatment of Small Cell Lung Cancer
8. CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350
9. NASDAQ Panel Grants Merge Technologies Additional Time to Regain Compliance
10. FDA Grants Resverlogix Approval to Commence a Phase 1 Clinical Trial for RVX-208
11. Maryland Stem Cell Commission Issues Nationwide Request for Applications for New Post-Doctoral Fellowship Grants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... ... August 27, 2015 , ... Capital Edge Consulting ... business problems, is pleased to announce their ranking as one of the top 5000 ... the fastest-growing private companies across the nation. , “It is truly an honor to ...
(Date:8/27/2015)... TORONTO , Aug. 27, 2015 /PRNewswire/ - ... Securities Exchange: PBT.U), and Biohaven Pharmaceutical Holding Company ... in a Phase I study of BHV-0223, a ... application (IND) regarding BHV-0223 and recently obtained clearance ... to proceed with human testing. Portage holds 54% ...
(Date:8/27/2015)... MENLO PARK, Calif. , Aug. 27, 2015 /PRNewswire/ ... company in the emerging field of regenerative medicine, today ... two investor conferences in the month of September.  ... Officer, will present at Rodman & Renshaw,s 17th Annual ... 10:25am ET/7:25am PT at the St. Regis Hotel in ...
(Date:8/27/2015)... DIEGO , Aug. 27, 2015 HUYA ... annual meeting of the Japan Society of HTLV-1, held ... Institute Auditorium. The purpose of the Society is to ... as the development of medical technology and research related ... and welfare. "HUYA is proud to support ...
Breaking Biology Technology:Capital Edge Consulting Makes Inc. 5000 List of America’s Fastest-Growing Private Companies 2Capital Edge Consulting Makes Inc. 5000 List of America’s Fastest-Growing Private Companies 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 2Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 4Asterias Biotherapeutics to Present at Upcoming Investor Conferences 2HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 2HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 3HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 4
... Imaging,Diagnostic Systems, Inc., (OTC Bulletin Board: IMDS) a pioneer ... CT Laser,Mammography (CTLM(R)) system, designed as an adjunct to ... applications were featured in,a cover story in the September ... was contributed by Eric Milne, MD, FRCR, FRCP, IMDS ...
... (Nasdaq: HALO ), a biopharmaceutical company developing ... announced,that its Board of Directors amended the Rights ... Agreement") in order to increase the ownership,threshold for ... Agreement from a fifteen percent (15%) ownership interest ...
... EDMONTON, Nov. 14 /PRNewswire-FirstCall/ - BioMS Medical Corp ... multiple sclerosis (MS), today,announced financial and operational results ... "During the quarter, we continued to maintain momentum ... the treatment of multiple,sclerosis," said Kevin Giese, President ...
Cached Biology Technology:New Optical Breast Cancer Imaging Technology Garners Cover Story in National Radiology Magazine 2New Optical Breast Cancer Imaging Technology Garners Cover Story in National Radiology Magazine 3Halozyme Therapeutics Amends Stockholder Rights Plan 2BioMS Medical announces third quarter 2007 results 2BioMS Medical announces third quarter 2007 results 3BioMS Medical announces third quarter 2007 results 4
(Date:8/5/2015)... York , August 5, 2015 ... report titled "Facial Recognition Market - Global Industry Analysis, ... the global market for facial recognition is forecast to ... driven by increased demand for surveillance systems by civil ... rising number of crimes and terrorist activities across the ...
(Date:8/4/2015)... (NASDAQ: AMRI ) today reported financial and operating results for ... , Second quarter contract revenue of $ 85.2 ... Adjusted contract margins of 26 % , ... in EPS from royalties in the current quarter , ... are very pleased to present another strong financial quarter, with all ...
(Date:7/31/2015)... de julio de 2015 BGI llevará a cabo ... del 22 al 25 de octubre de 2015, en ... conferencia celebra su décimo aniversario este año. Desde su ... de las reuniones anuales más influyentes del mundo en ... las conferencias científicas más dinámicas, entusiastas y amenas. ...
Breaking Biology News(10 mins):Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 2Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 3Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 4Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 5Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 6AMRI Announces Second Quarter 2015 Results 2AMRI Announces Second Quarter 2015 Results 3AMRI Announces Second Quarter 2015 Results 4AMRI Announces Second Quarter 2015 Results 5AMRI Announces Second Quarter 2015 Results 6AMRI Announces Second Quarter 2015 Results 7AMRI Announces Second Quarter 2015 Results 8AMRI Announces Second Quarter 2015 Results 9AMRI Announces Second Quarter 2015 Results 10AMRI Announces Second Quarter 2015 Results 11AMRI Announces Second Quarter 2015 Results 12AMRI Announces Second Quarter 2015 Results 13AMRI Announces Second Quarter 2015 Results 14AMRI Announces Second Quarter 2015 Results 15AMRI Announces Second Quarter 2015 Results 16AMRI Announces Second Quarter 2015 Results 17AMRI Announces Second Quarter 2015 Results 18AMRI Announces Second Quarter 2015 Results 19AMRI Announces Second Quarter 2015 Results 20AMRI Announces Second Quarter 2015 Results 21AMRI Announces Second Quarter 2015 Results 22AMRI Announces Second Quarter 2015 Results 23AMRI Announces Second Quarter 2015 Results 24La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3
... waters, nutrients must be removed in order to avoid eutrophication ... to animal and plant life. Robert Almstrand at the University ... removal of nitrogen from wastewater can be achieved by providing ... low levels of nutrients. The emission of wastewater to ...
... Many adolescents frequently expose their ears to loud sounds, ... may think that ,the doctor said that my hearing ... loud volume,. A new doctoral thesis from the University ... can be used to positively change adolescents, awareness and ...
... the University of California, Davis, have invented a superthin ... "The material itself (say, semiconductor wafers) would break ... of biomedical engineering. He and his fellow researchers have ... thick layer between two surfaces. Pan,s nanoglue, which conducts ...
Cached Biology News:New methods for better purification of wastewater 2Teaching about hearing can save young people's ears 2
... DNA Polymerase I from E. ... polymerase. The enzyme also contains ... The 5'?3' exonuclease activity enables ... and gaps in the DNA ...
... E. coli strain containing an overproducing ... M-MLV Reverse Transcriptase catalyzes the polymerization of ... hybrids(1). Full-length copies of large mRNAs, >10 ... has a much lower RNase H activity ...
... template-directed polymerization of nucleotides into duplex DNA ... possesses a 3?5 exonuclease activity or "proofreading" ... DNA replication, and also contains a 5?3 ... replace nucleotides in the growing strand of ...
Request Info...
Biology Products: